Error loading player: No playable sources found
P011
Impact of Patisiran on Activities of Daily Living and Functional Status in hATTR Amyloidosis
Explore related products in the following collection:
Speaker
Madeline Merkel, PharmD, MS
Sr. Manager of Medical Affairs, Alnylam Pharmaceuticals
General
Related Products
COVID-19 Restrictions Impact Psychosocial Health Outcomes of Adults with Cardiovascular Disease
A secondary analysis of psychosocial health outcomes reported by patients with cardiovascular disease during the COVID-19 social distancing guidelines. Findings include significant difference in social isolation, anxiety, depression and cognitive function…
Cardiovascular Disease Burden Before Hereditary Transthyretin Amyloidosis Diagnosis
BACKGROUND/INTRODUCTION • Hereditary transthyretin amyloidosis (hATTR or ATTRv [variant]) is a progressive and fatal disease often associated with infiltrative cardiac involvement • Cardiac involvement in ATTRv is associated with poor survival • Patients often have long-standing cardiac symptoms pr…
Evaluation of the Efficacy and Safety of AKCEA-TTR-L in Patients with Transthyretin-mediated Amyloid Cardiomyopathy: The CARDIO-TTRansform Study
Background: Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is a fatal condition caused by misfolding and aggregation of transthyretin (TTR). Despite the treatment with a TTR stabilizer, tafamidis, disease progression still occurs…
Genotypic and Phenotypic Differences and Similarities Among Patients With Inherited Cardiovascular Diseases: Insights From a Genetic Testing Program
INTRODUCTION •Hereditary transthyretin amyloidosis (hATTR/ATTRv) is a progressive and fatal disease caused by mutations in the transthyretin (TTR) gene •These mutations destabilize protein folding, resulting in amyloid deposits and causing multisystem dysfunction such as cardiomyopathy (CM), whose…
